KPV is a C-terminal tripeptide derivative of alpha-melanocyte-stimulating hormone (α-MSH) widely studied for its potent anti-inflammatory and mucosal restoration properties in preclinical research. This analytical guide reviews the chemical profile, cellular pathways, experimental models, and laboratory handling protocols for KPV.
KPV is a C-terminal tripeptide derivative of alpha-melanocyte-stimulating hormone (α-MSH) widely studied for its potent anti-inflammatory and mucosal restoration properties in preclinical research. This analytical guide reviews the chemical profile, cellular pathways, experimental models, and laboratory handling protocols for KPV.
KPV research focuses on the C-terminal tripeptide sequence Lysine-Proline-Valine, derived from alpha-melanocyte-stimulating hormone (α-MSH). In preclinical models, KPV demonstrates potent anti-inflammatory activity primarily through the inhibition of nuclear factor kappa B (NF-κB) nuclear translocation, reducing pro-inflammatory cytokine expression and preserving epithelial junctional complexes in intestinal mucosal tissue models.
Unlike its parent molecule α-MSH, KPV lacks melanogenic activity because it does not trigger classical melanocortin-1 receptor (MC1R) pathways associated with pigment synthesis. Instead, researchers utilize KPV in cell culture and animal tissue setups to evaluate anti-inflammatory intracellular transport mechanisms, antimicrobial peptide interaction, and targeted drug delivery systems without inducing pigmentary confounding factors.
KPV is a tripeptide defined by the amino acid sequence L-Lysyl-L-prolyl-L-valine (Lys-Pro-Val, molecular weight approximately 341.45 g/mol). Structurally, it represents amino acid residues 11 through 13 of the native 13-amino-acid peptide α-MSH. Despite its truncated length, the tripeptide retains the primary anti-inflammatory pharmacophore of α-MSH while eliminating high-affinity receptor binding to peripheral melanocortin receptors responsible for melanogenesis.
In biochemical assays, KPV exhibits high stability relative to larger peptide fragments due to the central proline residue, which imparts conformational rigidity to the peptide backbone. This structural feature limits susceptibility to non-specific cleavage by ubiquitous serum exopeptidases. Consequently, KPV serves as an efficient model for studying low-molecular-weight biological response modifiers in cellular signaling environments. Investigational setups often compare KPV against larger host defense peptides available in our all-peptides catalog to examine how molecular weight correlates with epithelial uptake rates.
The primary mechanism of action characterized in KPV research is the downregulation of inflammatory cascade initiation. Preclinical studies indicate that KPV enters target cells through active intracellular transport mediated by the oligopeptide transporter 1 (PepT1), a transmembrane transporter upregulated in inflamed tissues. Once inside the cytoplasm, KPV directly interacts with key regulatory nodes within the NF-κB signaling network.
Under unstimulated conditions, the transcription factor NF-κB remains sequestered in the cytoplasm bound to IκB inhibitory proteins. Upon inflammatory challenge (such as exposure to lipopolysaccharide or TNF-α), IκB is phosphorylated and degraded, allowing NF-κB to translocate to the nucleus and trigger transcription of pro-inflammatory genes. In vitro assays demonstrate that KPV suppresses IκB degradation and blocks the subsequent nuclear translocation of the p65 subunit of NF-κB. This blockade suppresses downstream transcriptional activation of pro-inflammatory cytokines, including interleukin-1 beta (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α).
A major area of interest in KPV research involves intestinal epithelial integrity and mucosal repair. In rodent models of experimental colitis—such as dextran sulfate sodium (DSS)-induced or trinitrobenzene sulfonic acid (TNBS)-induced colitis—administration of KPV resulted in measurable reductions in histologic inflammation scores, leukocyte infiltration, and mucosal ulceration.
In vitro models using Caco-2 cell monolayers reveal that KPV helps preserve transepithelial electrical resistance (TEER) following inflammatory challenge. The peptide maintains the structural organization of tight junction proteins, including zonula occludens-1 (ZO-1) and occludin. By attenuating inflammatory cell activation and reinforcing tight junctions, KPV limits paracellular permeability, making it a critical research tool for investigating gut mucosal homeostasis. Researchers examining barrier preservation mechanisms frequently reference our research library hub for foundational comparative data across mucosal model systems.
When designing preclinical protocols targeting tissue repair or inflammatory suppression, researchers often compare KPV to other well-characterized peptide candidates. Understanding how KPV performs relative to alternative compounds helps investigators select the appropriate signaling pathway targets for their experimental designs.
While KPV primarily functions via PepT1-mediated intracellular transport and NF-κB suppression, compounds like BPC-157 operate primarily through angiogenic upregulation, growth factor expression, and nitric oxide pathway modulation. Similarly, Larazotide acts as a tight junction receptor antagonist that specifically blocks zonulin-mediated disassembly without direct transcription factor inhibition. In antimicrobial and innate immunity assays, researchers often compare KPV with host defense peptides such as LL-37, which disrupts bacterial membranes directly while modulating toll-like receptor signaling. Selecting between these compounds depends on whether the primary hypothesis focuses on gene transcription regulation, tight junction dynamics, or broad-spectrum host defense.
Proper reconstitution is critical to maintain the structural stability and bioactivity of KPV in laboratory experiments. KPV is supplied as a lyophilized hydrophilic powder. For most cellular assays, sterile reconstituted stock solutions should be prepared using sterile, non-pyrogenic laboratory water or phosphate-buffered saline (PBS, pH 7.4).
To reconstitute KPV for laboratory use: Allow the vial to equilibrate to room temperature before opening to avoid condensation accumulation. Gently introduce the desired volume of sterile diluent along the inner glass wall of the vial. Allow the diluent to hydrate the cake, then gently swirl the vial until completely dissolved. Avoid vigorous vortexing or agitation, as shear forces can alter peptide solubility or cause foaming. For detailed protocols regarding solvent volume calculations and sterile filtration techniques, consult our comprehensive guide on bpc-157 research reconstitution parameters.
Lyophilized KPV exhibits excellent thermal stability when stored under appropriate ambient conditions. For long-term preservation, lyophilized vials must be maintained at -20°C or -80°C in a desiccated environment protected from direct light exposure. Under these conditions, the unconstituted peptide remains stable for up to 24 months.
Once reconstituted into aqueous solutions, KPV is more susceptible to enzymatic degradation, bacterial contamination, and hydrolysis. Reconstituted stock solutions should be aliquoted into single-use polypropylene microtubes to prevent repeated freeze-thaw cycles, which degrade peptide integrity. Reconstituted aliquots stored at 4°C should be used within 7 to 14 days, whereas frozen aliquots stored at -20°C maintain structural stability for up to 3 to 6 months. Never use frosted, self-defrosting freezers, as temperature fluctuations cause microscopic thaw cycles that accelerate peptide denaturation.
To ensure reproducible experimental outcomes, research facilities must verify the chemical quality and purity of KPV lots before beginning in vitro or animal studies. Low-purity peptide samples containing synthesis side-products or residual cleavage reagents can yield false-positive toxicity or aberrant signaling responses in cell culture.
High-performance liquid chromatography (RP-HPLC) is used to verify peptide purity, which should exceed 98.0% for quantitative research applications. Liquid chromatography-mass spectrometry (LC-MS) confirms exact molecular weight and amino acid sequence fidelity, ensuring the absence of deletion sequences. Furthermore, because KPV is frequently evaluated in inflammatory and immune pathways, background endotoxin levels must be rigorously controlled. Endotoxin contamination (lipopolysaccharides) activates TLR4 signaling, directly interfering with NF-κB assays. Laboratories should only utilize reagents tested via Chromogenic LAL (Limulus Amebocyte Lysate) assays with certified endotoxin levels below 0.01 EU/mg.
PX1 Research provides fully verified, high-purity research compounds synthesized specifically for rigorous laboratory applications. Every lot of KPV undergoes rigorous third-party testing in accredited ISO 17025 facilities to guarantee exact chemical identification, purity compliance, and safety parameters.
Our manufacturing processes strictly adhere to cGMP-compliant standards within USA-based synthesis facilities. Every product shipped is accompanied by a lot-specific Certificate of Analysis (COA) detailing RP-HPLC purity profiles, mass spectrometry verification, and quantitative endotoxin testing data. Institutional buyers and academic laboratories requiring high-volume supplies or specialized batch documentation can explore custom fulfillment through our wholesale program. Orders placed Monday through Friday ship same-day from our California and Arizona logistics hubs to support continuous research schedules.
What is the primary chemical structure and sequence of KPV?
KPV is a synthetic tripeptide consisting of Lysine-Proline-Valine. It corresponds to the C-terminal amino acid sequence (residues 11–13) of alpha-melanocyte-stimulating hormone (α-MSH).
Does KPV induce melanogenesis in laboratory models?
No. Preclinical research demonstrates that KPV lacks the central melanocortin receptor-binding core required to activate MC1R pathways responsible for melanin synthesis, isolating its study to anti-inflammatory and epithelial transport mechanisms.
How does KPV enter target intestinal epithelial cells?
In vitro studies show that KPV is actively transported across cell membranes via the PepT1 oligopeptide transporter, which is highly expressed on apical membranes of intestinal epithelial cells, particularly during inflammatory states.
What solvents are suitable for reconstituting KPV in cell culture assays?
KPV is readily soluble in aqueous buffers including sterile laboratory-grade water, phosphate-buffered saline (PBS), or standard cell culture media (e.g., DMEM or RPMI) adjusted to neutral pH.
What is the recommended endotoxin limit for KPV in research applications?
For reliable cellular signaling and immunological research, KPV should maintain endotoxin levels below 0.01 EU/mg to prevent background activation of Toll-like receptor 4 (TLR4) and NF-κB pathways.
How should lyophilized KPV be stored upon receipt?
Lyophilized KPV powder should be stored at -20°C or -80°C in a dry environment protected from light to maintain structural integrity and shelf life.
What analytical methods are required to verify KPV quality?
Quality verification requires Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) for purity assessment, Mass Spectrometry (MS) for mass verification, and LAL assays for endotoxin quantification.
Are PX1 Research compounds approved for clinical use or human consumption?
No. All products supplied by PX1 Research are intended strictly for laboratory research, in vitro experimentation, and preclinical research use only. They are not for human or veterinary administration.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.